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ABSTRACT
Objective: Electronic health records (EHRs) are a rich source of information on human diseases, but the infor-
mation is variably structured, fragmented, curated using different coding systems, and collected for purposes
other than medical research. We describe an approach for developing, validating, and sharing reproducible
phenotypes from national structured EHR in the United Kingdom with applications for translational research.
Materials and Methods: We implemented a rule-based phenotyping framework, with up to 6 approaches of
validation. We applied our framework to a sample of 15 million individuals in a national EHR data source (popu-
lation-based primary care, all ages) linked to hospitalization and death records in England. Data comprised con-
tinuous measurements (for example, blood pressure; medication information; coded diagnoses, symptoms,
procedures, and referrals), recorded using 5 controlled clinical terminologies: (1) read (primary care, subset of
SNOMED-CT [Systematized Nomenclature of Medicine Clinical Terms]), (2) International Classification of
Diseases–Ninth Revision and Tenth Revision (secondary care diagnoses and cause of mortality), (3) Office of
Population Censuses and Surveys Classification of Surgical Operations and Procedures, Fourth Revision (hospi-
tal surgical procedures), and (4) DMþD prescription codes.
Results: Using the CALIBER phenotyping framework, we created algorithms for 51 diseases, syndromes, bio-
markers, and lifestyle risk factors and provide up to 6 validation approaches. The EHR phenotypes are curated
in the open-access CALIBER Portal (https://www.caliberresearch.org/portal) and have been used by 40 national
and international research groups in 60 peer-reviewed publications.
Conclusions: We describe a UK EHR phenomics approach within the CALIBER EHR data platform with initial evi-
dence of validity and use, as an important step toward international use of UK EHR data for health research.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unre-
stricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. 1
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INTRODUCTION
The UK National Health Service (NHS) offers international
researchers opportunities to explore “cradle to grave” longitudinal
electronic health record (EHR) phenotypes at scale. It is one of the
few countries that combines a single-payer-and-provider compre-
hensive healthcare system, free at the point of care, with extensive
national data resources across the entire population of 65 million.
Patients are identified by a unique healthcare-specific identifier
which enables linkage of patient data across EHR sources and the
creation of longitudinal phenotypes that span primary and second-
ary care.1 Over 99% of people are registered with a general practi-
tioner (GP) and structured primary care data collected
electronically have been used by UK, U.S. and other researchers for
decades.2 Furthermore, these national EHR data sources are being
linked with large-scale consented genomic resources, for example,
the 100 000 Genomes Project (also known as Genomics England)3
and UK Biobank,4–6 and enable the investigation of simple or com-
plex traits across participant populations with diverse genetic
backgrounds.7
The UK EHR landscape differs from the United States and else-
where in important ways. Although the United Kingdom, unlike the
United States, has the opportunity to establish a national approach,
it faces the common challenge that EHR for primary care and hospi-
tal care are handled by different data providers and are kept sepa-
rately, with independent access requirements.8,9 Significant progress
has been made by U.S. initiatives such as Electronic Medical
Records and Genomics (eMERGE),10 BioVU,11 Million Veteran
Program,12 and All Of Us,13 and in Canada,14 Australia,15 Swe-
den,16 and Denmark.17 In the United Kingdom, however, there has
been no recognized phenotyping framework or go-to resource for
EHR researchers for systematically creating, curating and validating
(rule-based or otherwise) EHR-derived phenotypes, obtaining infor-
mation on controlled clinical terminologies, sharing algorithms, and
communicating best approaches. Structured primary care EHR have
been used in >1800 published studies,18 but only 5% of studies pub-
lished sufficiently reproducible phenotypes,19 while significant het-
erogeneity exists (one review reported 66 asthma definitions).20
Current UK initiatives19,21,22 for curating EHR-derived phenotypes
focus on lists of controlled clinical terminology terms (referred to as
code lists) rather than self-contained phenotypes (terms, implemen-
tation, and validation evidence).
The scope of our research focuses on rule-based algorithms, as
the majority of research studies (with some exceptions)23,24 using
UK EHR utilize this approach for creating EHR-derived pheno-
types.25 The main use case for CALIBER phenotypes and the ap-
proach presented in the manuscript is observational research (which
is also the main stakeholder group of UK EHR): (1) high-resolution
clinical epidemiology using national EHR examining disease
etiology or prognosis, or (2) genetic epidemiology studies through
the UK Biobank and Genomics England investigating simple and
complex traits across populations. Our aspiration, however, is for
CALIBER phenotypes to be adopted by the NHS in terms of com-
putable knowledge which can be integrated in the healthcare system
and used for interventional studies and clinical guidelines. Each of
these use cases, however, has a different threshold on what is consid-
ered adequate performance, and we adopted a systematic and robust
validation approach to quantify phenotype performance.
EHR phenotype validation is a critical process guiding their sub-
sequent use in research or care.26,27 There are multiple sources of
evidence or study designs that contribute to building confidence
in the validity of an EHR phenotype for a particular purpose.
Countries may also differ in the opportunities for validation: for ex-
ample, in the United Kingdom, cross-referencing against multiple
EHR sources, prognostic validation, and risk factor validation are
all made possible by nationwide population-based records.28–32 In
contrast with the United States, only recently have scalable methods
been developed to access the entire hospital record for expert re-
view,33 and text corpora are not available at scale.34 There have
been few previous studies35 of the validity of International Classifi-
cation of Disease and Health Related Problems–Tenth Revision
(ICD-10) terms36 in the United Kingdom against hospital records be-
cause introduction of hospital EHRs is recent (for example, there
are only 3 hospitals that have achieved stage 6 on the Healthcare In-
formation and Management Systems Society Electronic Medical Re-
cord Adoption Model.37
We have developed the CALIBER EHR platform for the United
Kingdom by adopting and extending best practices from leading ini-
tiatives and consortia (for example, eMERGE, Million Veteran Pro-
gram, BioVU) with regards to creating, evaluating, and
disseminating EHR-derived phenotypes for research. Specifically,
these practices, which were previously not systematically followed
in the UK EHR community before CALIBER include (1) establishing
a robust and iterative phenotype creation process involving multiple
scientific disciplines, (2) systematically curating EHR-derived
phenotypes, (3) using methods for enhancing reproducibility, and
(4) undertaking and reporting robust phenotype validation analyses.
Here, we define a framework for enabling EHR phenotyping in a
scalable and reproducible manner. Algorithm reproducibility was
defined similarly to Goodman’s “methodology reproducibility,”38
that is, providing a systematic and precise description of the algo-
rithm components, logic, implementation, and evidence of validity
that would enable national or international independent researchers
to create, apply, and evaluate CALIBER phenotyping algorithms in
local similar data sources. We present a systematic validation frame-
work for assessing accuracy consisting of up to 6 approaches of evi-
dence (expert review to prognostic validation) and disseminating
through a centralized open-access repository. We have chosen heart
failure (HF), acute myocardial infarction (AMI), and bleeding as
examples of medical conditions that exemplify the strengths of na-
tional linked UK EHR and the nontrivial challenges researchers en-
counter.
MATERIALS AND METHODS
We developed an iterative and collaborative approach for creating
and validating rule-based EHR phenotyping algorithms using UK
structured EHR. The approach involved expert review interwoven
with data exploration and analysis. An EHR phenotyping algorithm
translates the clinical requirements for a particular patient to be con-
sidered a case into queries that leverage EHR sources stored in a re-
lational database and extracts disease onset, severity, and subtype
information. In the following sections we describe the platform, the
algorithm development process, and validation consisting of 6
approaches of evidence.
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UK primary care EHR, hospital billing data, and
cause-specific mortality in the CALIBER platform
The CALIBER platform39 is currently built around 4 national EHR
data sources (Figure 1) deterministically linked using NHS number
(unique 10-digit identifier assigned at birth or first interaction), gen-
der, postcode, and date of birth; 96% of patients with a valid NHS
number successfully linked.40
The baseline cohort is composed of a national primary care EHR
database, the Clinical Practice Research Datalink (CPRD).41 Pri-
mary care has used computerized health records since 2000 and gen-
eral practices use one of several EHR systems. CPRD contains
longitudinal primary care data (extracted from the Vision and Egton
Medical Information Systems clinical information systems) on diag-
noses, symptoms, drug prescriptions, vaccinations, blood tests, and
risk factors irrespective of disease status and hospitalization. The
CPRD uses Read42 terms (112 806 terms; subset of the International
Health Terminology Standards Development Organization
SNOMED-CT [Systematized Nomenclature of Medicine Clinical
Terms])42 to record information. Prescriptions are recorded using
Gemscript (a commercial derivative of the NHS Dictionary of Medi-
cines and Devices [dmþd])43 (72 664 entries). The CPRD contains
>10 billion rows of data from >15 million patients (from all the
contributing primary care practices, irrespective of consent to link-
age) shown to be representative in terms of age, sex, mortality, and
ethnicity44–46 and of high validity.47
Hospital Episode Statistics (HES) (https://digital.nhs.uk/)48 con-
tains administrative data on diagnoses and procedures generated
during hospital interactions. Diagnoses are recorded using the ICD-
10 and procedures using the Office of Population Censuses and Sur-
veys Classification of Surgical Operations and Procedures, Fourth
Revision (10 713 terms, similar to Current Procedural
Terminology).49 Up to 20 primary and secondary discharge diagno-
ses are recorded per finished consultant episode. The Myocardial Is-
chaemia National Audit Project (MINAP) is a national disease and
quality improvement registry capturing all acute coronary syndrome
events across England. MINAP contains diagnostic, severity and
treatment information using 120 structured data fields.50 The Office
for National Statistics (ONS) contains socioeconomic deprivation
using the Index of Multiple Deprivation51 and physician-certified
cause-specific mortality (underlying and up to 14 secondary causes
using International Classification of Diseases–Ninth Revision [ICD-
9] or ICD-10).
Data quality
Primary care
Our analyses incorporated primary care EHR data quality metrics
across 2 dimensions: at the patient level and at the primary care
practice level.41
Patient-level data quality. In line with previous research using UK
primary care EHRs from the CPRD and CPRD guidance, we only
utilized patients which were marked as “acceptable for research” by
the CPRD. Patients are labeled as acceptable through an algorithmic
process that identified and excludes patients with noncontinuous
follow-up and patients with poor data according to a predefined list
of data quality metrics (for example, empty date of first registration,
first registration before date of birth, invalid gender, missing or in-
correct dates across all recorded healthcare episodes). We addition-
ally excluded records in which the date was invalid or malformed or
in the future occurring after the last date of data collection.
Practice level. The overall quality of the data recorded in a primary
care practice is algorithmically marked by an “up to standard
Figure 1. The CALIBER platform (https://www.caliberresearch.org) links national structured electronic health records (EHRs) across primary care, secondary care,
and mortality for research. EHR-derived phenotypes are created using an iterative methodology and 6 independent approaches of evidence are generated to as-
sess algorithm accuracy. More than 50 phenotypes are published in an open-access resource, the CALIBER Portal (https://www.caliberresearch.org/portal), and
are used in >60 publications.
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(UTS)” date by the CPRD. The UTS date is deemed as the date at
which data in the practice are considered to have continuous high-
quality data fit for use in research. The algorithm used to derive this
date is based on 2 concepts: (1) gap analysis (assurance of continuity
in data recording and establishing if any unexpected and prolonged
gaps in recording exist) and (2) death recording (observing the
expected and actual deaths recorded at a practice over time by
taking into account season and geographical variation in death rates
and establishing if any gaps in recording exist). In both of these
cases, the UTS date is set to the latest of these dates.
Completeness patterns of key clinical covariates such as risk
factors (for example, smoking status, blood pressure, body mass in-
dex) has been previously shown to have rapidly increased after the
introduction of a financial incentives framework (Quality and Out-
comes Framework) that encourages GPs to record key data items.41
Secondary care
The HES Admitted Patient Care data are collected for all admissions
to all NHS secondary healthcare providers. The NHS funds 98%-
99% of hospital activity in England. HES Admitted Patient Care
data are administrative data collected for reimbursement of hospital
activity and are postdischarge derived by clinical coders according
to standardized rules for translating information from discharge
summaries into diagnosis (ICD-10) and surgical procedure terms
(Office of Population Censuses and Surveys Classification of Surgi-
cal Operations and Procedures, Fourth Revision) terms.48 The over-
arching reimbursement framework, Payment-By-Results (a fixed-
tariff case mix–based payment system)52 provides financial incen-
tives for hospitals to improve their coding accuracy and depth and
ensure accurate reimbursement. This has led to an increase in the
number of diagnosis terms recorded and coding accuracy (primary
diagnoses accuracy was 96% [interquartile range, 89.3%-96.3%])
when compared with expert review of case notes.53 The NHS Digi-
tal Data Quality Maturity Index provides a per hospital overall
score for clinical data quality in term of data field and hospitaliza-
tion episode completeness on a quarterly basis.54
Algorithm development
The development pipeline was a collaborative and iterative process
involving researchers from a diverse set of scientific backgrounds
(for example, clinicians, epidemiologists, computer scientists, public
health researchers, statisticians). An iteration refers to an adjustment
in the computational strategy to derive the phenotype in question,
based on data-driven examinations of its internal validity and
according to the clinical context. The number of development itera-
tions was proportionate with the complexity of the clinical pheno-
type: algorithms leveraging multiple sources required multiple
iterations and substantially more clinician input.
We initially defined search strategies for identifying relevant di-
agnosis terms and their synonyms which were selected based on in-
put from clinicians, existing literature, national guidelines and by
consulting medical vocabulary repositories (for example, Unified
Medical Language System Metathesaurus.)55,56 Two clinicians inde-
pendently classified identified terminology terms (disagreements re-
solved by third) into nonoverlapping categories: (1) prevalent (for
example, “history of heart failure”), (2) possible (for example,
“congestive heart failure monitoring”), and (3) incident (potentially
subclassified [for example, “chronic congestive heart failure,”
“acute left ventricular failure,” “heart failure not otherwise spec-
ified”]). Similarly, we identified and classified coded symptoms
recorded in primary care EHR. Many CALIBER phenotyping algo-
rithms combine coded diagnosis, symptom information, continuous
measurements (for example, laboratory values or other physiologi-
cal measurements), and medication prescription information in a
rule-based fashion (for example, hypertension is defined using con-
tinuous blood pressure, coded diagnoses, blood pressure–lowering
prescriptions, and comorbidities). We generated ad hoc rules to rec-
oncile (1) coding differences across EHR sources with respect to the
granularity of diagnosis, (2) the presence of multiple terms (for ex-
ample, multiple different ethnicity entries, and (3) transience in cod-
ing (for example, ICD-9 was used for recording the cause of death
before 2000). In primary care EHR, identified Read terms were eval-
uated in terms of their information content and subsequent ability
to ascertain a phenotype reliably.
Primary care EHRs contain over 450 structured data items for
recording continuous measurements (for example, blood markers).
For continuous phenotypes (for example, blood pressure), we nor-
malized data quality by identifying the relevant units, specified unit
conversions (where required), and defined valid value ranges. For
example, the neutrophil count structured data area contained both
the absolute values and percentages, and these had to be differenti-
ated by supplementary Read terms and by checking the distribution
of values by unit. Sometimes values were obviously on the wrong
scale (for example, hemoglobin) in which some values were distrib-
uted as if measured in grams per liter but had (presumably incorrect)
units recorded as grams per deciliter. Zero values caused particular
problems; they could be impossible and represent missing data in
some cases (for example, ferritin) but might be true zeroes represent-
ing undetectable values in other cases (eg, basophils). Careful inves-
tigation by units and Read term was required to avoid creating
Missing Not at Random data (if the zeroes were true) or false data
(if the zeroes were false). Definition of valid ranges for values was
also problematic, as we wanted to exclude erroneous values without
excluding true physiologically extreme values.
Validation: systematic evaluation using 6 approaches
Obtaining and curating evidence of phenotype validity is an essential
component of the phenotyping process. We evaluated EHR-derived
phenotypes across up to 6 different approaches of providing of evi-
dence of phenotype validity, acknowledging that that the use case
will inform which validation(s) are most important. For example,
phenotyping algorithms developed for disease epidemiology (for ex-
ample, screening or disease surveillance) might be designed for
higher sensitivity whereas those used in genetic association studies
might be designed to maximize positive predictive value (PPV). We
provide details of these validation approaches in the following
sections.
Cross-EHR source concordance
For EHR-derived cases of AMI, HF, and bleeding, we quantified the
percentage of cases identified in each source, quantified the overlap
between sources, and evaluated per-source completeness and diag-
nostic validity. Additionally, we used a disease registry (MINAP) as
a reference to derive the PPV of AMI diagnoses recorded in hospital
EHR (HES), that is, the probability that an AMI diagnosis recorded
in HES was indeed an AMI as ascertained by MINAP (that contains
information on AMI ascertainment such as electrocardiogram
results and troponin measurements) rather than unstable angina or a
noncardiac diagnosis. We did not calculate sensitivity and specificity
relative to MINAP given that MINAP does not include all cases of
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AMI, as it is a disease registry that requires bespoke data entry by
audit staff separate from clinical care or coding. It is therefore not
possible to use MINAP as a gold standard to evaluate hospital EHR
(HES) in relation to completeness of detection of AMI (sensitivity)
or non-MI (specificity). However, there is a concern that HES data
may be inaccurate, and MINAP can be used to evaluate its PPV for
the subset of cases with a MINAP record for the event, in which the
exact diagnosis in MINAP can be considered a “gold standard.”
Case note review
We evaluated the performance of the secondary care component of
the bleeding phenotype by assessing the ability of the diagnosis terms
(ICD-10) utilized by the phenotype to correctly identify hospitalized
bleeding events in 2 independent hospital EHR sources. Two clini-
cians (blinded to the ICD-10 diagnosis terms) reviewed the entire hos-
pital record (charts, referral letters, discharge letters, imaging reports)
for 283 completed patient hospital episodes across 2 large hospitals
(University College London Hospitals, King’s College Hospital).
Bleeding assignments from the clinicians review was compared with
those from the phenotyping algorithm and we estimated the PPV, neg-
ative predictive value (NPV), sensitivity, and specificity using the case
review data as the “gold standard.” We extracted hospital data
(14 364 947 words) using CogStack57 from the consented SIGNUM
(Stroke InvestiGation Network-Understanding Mechanisms) study.
Consistency of risk factor–disease associations from non-EHR
studies
For all exemplars, we produced and reported hazard ratios (HRs)
and 95% confidence intervals (CIs) of known risk factors from Cox
proportional hazards models adjusted for age, sex, and other cova-
riates. We evaluated the ability of obtaining consistent estimates (in
terms of direction and magnitude) with risk factor associations de-
rived from non-EHR research-driven studies.
Consistency with prior prognosis research
We produced Kaplan–Meier cumulative incidence curves at appro-
priate time intervals and endpoints and stratified by EHR source.
We evaluated the observed prognostic profiles with previously
reported evidence for example observing different survival patterns
between patients diagnosed with HF in CPRD but never hospitalized
compared with patients diagnosed in HES.
Consistency of genetic associations
Similar to previous studies, we attempted to replicate previously
reported associations between genetic variants and diseases discovered
from non-EHR studies (for example, research-driven observational
cohort studies or interventional studies). The ability of EHR-derived
phenotypes to replicate previously discovered associations derived
from non-EHR studies and observing similar direction and magnitude
of association reinforces the evidence toward the overall validity of
the EHR phenotype.58 Using PLINK,59 we extracted genetic variants
associated with AMI reaching genome-wide significance (P<5 
108) from publicly available 1000 Genomes–based genome-wide
association study summary data (“CARDIoGRAMplusC4D -
mi.additive.Oct2015”) in the CARDIoGRAMplusC4D60 consortium.
In the UK Biobank, we identified AMI cases in linked hospital and
mortality EHR using the CALIBER AMI phenotype and defined con-
trols as noncase participants with no self-reported record of AMI at
baseline. We estimated the association of genetic variants and AMI us-
ing logistic regression with an underlying additive model in PLINK
adjusting for the first 10 principal components, age and sex. Replica-
tion was defined as the single nucleotide polymorphism being associ-
ated with AMI in the UK Biobank (Bonferroni-adjusted P< .0016)
with a concordant direction of effect with CARDIOGRAMPlusC4D.
External populations
We assessed the validity of developed algorithms by implementing
them in external data sources (UK or elsewhere) and examining con-
sistency of results in the evaluation criteria.
Phenotype dissemination
We generated textual descriptions of algorithms with explicit detail
on the logic behind the algorithm (preprocessing, cross-source rec-
onciliation, quality checks) in a clinician-friendly manner. We gener-
ated flowchart representations accompanied by pseudocode for
facilitating the translation of the algorithm to Structured Query Lan-
guage (SQL) queries. We created entries in the CALIBER Portal
(Figure 2) describing implementation details across sources, research
outputs, validation evidence and a Digital Object Identifier.61 We
created an open-source R library for manipulating clinical terminol-
ogies (http://caliberanalysis.r-forge.r-project.org/) using a custom
file format including metadata (for example, naming, version,
authors, timestamp).
Ethical approval
The CPRD has broad ethical approval for purely observational re-
search using pseudonymized linked primary or secondary care data
for supporting medical purposes that are in the interests of patients
and the wider public. Linkages were performed by NHS Digital, the
statutory body in England responsible for providing core healthcare
information technology and curating many of the national datasets.
This study was approved by the Medicines and Healthcare Products
Regulatory Agency Independent Scientific Advisory Committee
(protocol references: 11_088, 12_153R, 16_221, 18_029R2,
18_159R).
RESULTS
Using the CALIBER EHR phenotyping approach described here, we
curated over 90 000 terms from 5 controlled clinical terminologies
to create 51 validated phenotyping algorithms (35 diseases or syn-
dromes, 10 biomarkers, 6 lifestyle risk factors). In this manuscript,
we used 3 exemplar phenotypes: HF (https://www.caliberresearch.
org/portal/phenotypes/heartfailure), bleeding (https://www.caliber-
research.org/portal/phenotypes/bleeding), and AMI (https://www.
caliberresearch.org/portal/phenotypes/acutemyocardialinfarction).
Table 1 provides a complete list of published, peer-reviewed pheno-
types and the approaches of evidence supporting their validity. CAL-
IBER phenotypes have been used by 40 national and international
research groups in 60 peer-reviewed publications.62 The CALIBER
Portal (http://www.caliberresearch.org/portal) opened in October
2018 to the community and provides a centralized resource for cu-
rating EHR-derived phenotypes.
Cross-EHR source concordance
The PPV of AMI (the probability that the diagnosis recorded in
MINAP was AMI rather than unstable angina or a noncardiac diag-
nosis) was 92.2% (6660 of 7224; 95% CI, 91.6%-92.8%) in CPRD
and 91.5% (6851 of 7489; 95% CI, 90.8%-92.1%) in HES
(Figure 3). Among the 17 964 patients with at least 1 record of
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nonfatal AMI, 13 380 (74.5%) were recorded by CPRD, 12 189
(67.9%) by HES, and 9438 (52.5%) by MINAP. Overall, 5561
(31.0%) of patients had AMI recorded in 3 sources (32.0% within
90 days), with 11 482 (63.9%) in at least 2 sources. For 89 554 HF
cases, 26% were recorded in CPRD only, 27% in both CPRD and
HES, and 34% in HES only, and 13% had HF as cause of death
without a previous record elsewhere. In 39 804 bleeding cases,
59.4% were captured in CPRD and 50.2% in HES, with 3.8%
events in ONS. Allowing a 30 day window, only 13.2% of events
were captured in 2 or more sources. Similarly, a very small propor-
tion (13.2%) of bleeding cases identified were captured in multiple
data sources.
Case note review
We tested the validity of ICD-10 terms used in our bleeding pheno-
type and found an NPV of 0.94 (95% CI, 0.90-0.97) and a PPV of
0.88 (88% of bleeding events identified by the ICD-10 terms utilized
in the CALIBER bleeding phenotype were indeed bleeding events
according to the independent review of the entire hospital record by
2 clinicians, blinded to the term assignment. We found that ICD-10
coded events underestimate the occurrence of bleeding, with a sensi-
tivity estimate of 0.48, consistent with a previous study where 38%
of hospitalized bleeding events were not captured by coded terms.63
Specificity was found to be 0.99 (95% CI, 0.97-1.00), indicating a
very low number of false positive bleeding events.
Etiology
Figure 4 shows age- and sex-adjusted HRs from Cox proportional
hazards models for HF and CVD risk factors (smoking, type 2 dia-
betes, systolic blood pressure, heart rate) in CALIBER and non-EHR
studies.
Prognosis
In 20 819 AMI cases, we found that patients with events recorded in
only 1 source had higher mortality than did those recorded in more
than 1 source (age- and sex-adjusted HR, 2.29; 95% CI, 2.17-2.42;
P< .001).29 Among patients with AMI recorded in only 1 source,
those only in CPRD had the highest mortality on the first day but
the lowest mortality thereafter. Among patients with AMI recorded
in HES or MINAP, those in MINAP had lower coronary mortality
in the first month (age- and sex-adjusted HR, 0.33; 95% CI, 0.28-
0.39; P< .001) but similar mortality for noncoronary events (HR,
1.12; 95% CI, 0.90-1.40; P¼ .3). After the first month, patients
with AMI in CPRD had about half the hazard of mortality of
patients with AMI recorded in 1 of MINAP or HES (age- and sex-
adjusted HR, 0.49; 95% CI, 0.40-0.60; P< .001). In 89 994 HF
cases, we observed 51 903 deaths and generated Kaplan–Meier
curves for 90-day survival. Adjusted for age and sex, HF was
strongly associated with mortality, with HRs for all-cause mortality
ranging from 7.01 (95% CI, 6.83-7.20) to 7.23 (95% CI, 7.03-
7.43), and up to 15.38 (95% CI, 15.02-15.83) for patients in CPRD
with acute HF hospitalization, CPRD only, and HES only, com-
pared with an age- and sex-matched reference population. Age, con-
comitant chronic obstructive pulmonary disease, and diabetes were
among the strongest predictors of death. Compared with patients
with no bleeding, patients with bleeding recorded in CPRD and HES
were at increased risk of all-cause mortality and atherothrombotic
events (HR all-cause mortality for CPRD bleeding, 1.98; 95% CI:
1.86-2.11; and HR all-cause mortality for HES bleeding, 1.99; 95%
CI: 1.92-2.05).
Genetic associations
In the CARDIoGRAMplusC4D genome-wide association study
summary data, we identified 31 independent variants associated
with AMI by linkage disequilibrium clumping (R2 < 0.001, 250 kb)
genetic variants reaching genome-wide significance (P<5  10–8).
In the UK Biobank, we identified 8281 AMI cases and 394 933 con-
trols, and excluded 5266 participants from the analysis due to self-
reported AMI at baseline. From 31 previously reported single nucle-
otide polymorphisms, 31 (100%) had P< .05 with same direction,
with 26 (83.8%) passing Bonferroni correction (P< .0016) (Supple-
mentary Table 1).
External populations
We assessed the validity of the AMI, HF, and bleeding phenotypes
by comparing long-term outcomes (any cause death, fatal AMI or
stroke, hospital bleeding) in AMI survivors in England (n¼4653),
Sweden (n¼5484), United States (n¼53 909), and France
(n¼961).64 We found consistent associations with 12 baseline prog-
nostic factors (age, sex, AMI, HF, diabetes, stroke, renal disease, pe-
ripheral arterial disease, atrial fibrillation, hospital bleeding, cancer,
chronic obstructive pulmonary disease) and each outcome. In each
country, we observed high 3-year crude cumulative risks of all-cause
death (from 19.6% [England] to 30.2% [United States]), with the
Figure 2. CALIBER Portal entry for the heart failure phenotype (available at https://www.caliberresearch.org/portal/phenotypes/heartfailure). Each entry in the Por-
tal contains implementation details on the logic and the terms from controlled clinical terminologies associated with the phenotyping algorithm. Additionally, the
6 approaches of validation evidence are presented and the research output that has used the phenotype is provided.
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Table 1. Overview of published, peer-reviewed EHR phenotypes derived from the CALIBER platform and the approaches of validation evi-
dence - More information available on the CALIBER Portal https://www.caliberresearch.org/portal/phenotypes
Phenotype EHR data source Validation evidence
Primary care Secondary care Death Cross-source Case-note review Prognosis Etiology Genetic Cross-country
Disease or syndrome
AAA      
AMI        
AD     
AF       
Uveitis   
Bleeding        
Bullous disorder    
CHD     
Depression    
Diabetes    
Giant cell arteritis    
HF      
HIV     
Hypertension     
HCM    
Influenza  
MS    
PAD      
Polymyalgia    
PBC    
Psoriasis    
Dementia NOS     
RA    
SA     
Intracerebral hemorrhage      
Ischemic stroke      
SAH      
Stroke NOS      
SCD      
Systemic sclerosis    
TIA      
UCD     
UA     
Vascular dementia     
Obesity    
Biomarkers
Blood pressure  
Eosinophils  
Heart rate  
Lymphocytes  
Neutrophils  
White blood cells   
LDL cholesterol  
HDL cholesterol  
Triglycerides  
BMI   
Lifestyle risk factors and other
Alcohol  
Ethnicity   
Pregnancy   
Sex  
Smoking  
Deprivation  
AAA: abdominal aortic aneurysm; AD: Alzheimer’s disease; AF: atrial fibrillation; AMI: acute myocardial infarction; BMI: body mass index; CHD: coronary
heart disease; EHR: electronic health record; HCM: hypertrophic cardiomyopathy; HDL: high-density lipoprotein; HF: heart failure; HIV: human immunodefi-
ciency virus; LDL: low-density lipoprotein; MS: multiple sclerosis; NOS: not otherwise specified; PAD: peripheral arterial disease; PBC: primary biliary cirrhosis;
RA: rheumatoid arthritis; SA: stable angina; SAH: subarachnoid hemorrhage; SCD: sudden cardiac death; TIA: transient ischemic attack; UA: unstable angina;
UCD: unheralded coronary death.
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composite of AMI, stroke, or death (from 26.0% [France] to 36.2%
[United States]) and hospitalized bleeding (from 3.1% [France] to
5.3% [United States]). Adjusted risks were similar across countries,
but higher in the United States for all-cause death (Relative Risk
(RR) United States vs. Sweden, 1.14; 95% CI, 1.04-1.26) and hospi-
talized bleeding (RR United States vs. Sweden, 1.54; 95% CI, 1.21-
1.96). Similar analyses were performed for white blood cells, com-
paring all-cause mortality in England and New Zealand.65,66 High
white blood cells within the reference range (8.65-10.05109/L)
was associated with significantly increased mortality compared with
the middle quintile (6.25-7.25109/L; adjusted HR for England,
1.51; 95% CI, 1.43-1.59; adjusted HR for New Zealand, 1.33; 95%
CI, 1.06-1.65).
DISCUSSION
In this study, we describe the CALIBER phenotyping approach,
which has been used to produce 51 validated phenotyping algo-
rithms which capture disease status, biomarker values, and lifestyle
risk factors across 4 UK national EHR data sources spanning pri-
mary care, hospital admissions, a disease registry, and a mortality
register. Creating nationally applicable phenotypes leveraging mul-
tiple EHR sources has, until recently, been a challenging, time-
consuming, unreplicable, and somewhat opaque process without
any centralized resources. Research studies require precise pheno-
type definitions but phenotypic information found in EHR is typi-
cally inconsistent and of variable data quality. These problems are
exacerbated when linking data across healthcare settings (primary
care and hospital admissions), as each source records information
using different healthcare processes, disparate formats, and termi-
nologies and interact with fundamentally different patient popula-
tions. Complementary initiatives exist,19 but these are different
from CALIBER, as they focus on curating code lists. We have taken
a different approach and define an EHR phenotype as a combina-
tion of 3 essential elements: controlled clinical terminology terms,
implementation logic, and validation evidence, all of which are cu-
rated on the CALIBER Portal. Compared with the Phenotype
Knowledgebase developed by the eMERGE consortium, CALIBER
includes additional approaches of validation, such as etiological
and prognostic across population samples, but lacks comprehensive
detailed PPV or NPV measurements that are made possible by the
availability of text and access to case notes at scale in the United
States.
CALIBER phenotyping algorithms use structured information
on diagnoses, symptoms, referrals, prescriptions, and procedures,
which are recorded using 5 controlled clinical terminologies and
continuous measurements to extract disease onset and severity. The
actual phenotyping algorithm production was lengthy and labor in-
tensive and usually involved a large number of iterations although
the exact number of person hours was difficult to ascertain. A par-
ticular challenge was the need to reconcile differences in granularity
of diagnosis terms used in primary care and secondary care EHR, as
each healthcare setting utilizes different clinical terminologies to re-
cord information (Read in primary care, ICD-10 in secondary care).
For example, in HF, the Read controlled clinical terminology
allowed us to potentially distinguish between the 2 main congestive
heart failure types: heart failure with normal or preserved ejection
fraction (Read term “G583.11 HFNEF - heart failure with normal
Figure 3. Assessing the recording and concordance of 3 electronic health record (EHR)–derived phenotypes (heart failure, nonfatal acute myocardial infarction
[AMI], and bleeding) across 3 EHR data sources: primary care (Clinical Practice Research Datalink [CPRD]), hospital care (Hospital Episode Statistics [HES]), and
mortality (Office for National Statistics [ONS]) or disease registry data (Myocardial Ischaemia National Audit Project [MINAP]). Only a very small proportion (9%
for heart failure, 31% for AMI, and <1% for bleeding) of cases are identified concurrently by all 3 data sources. ICD-10: International Classification of Diseases–
Tenth Revision.
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ejection fraction”) and heart failure with reduced ejection function
or left ventricular systolic dysfunction (Read term “G5yy900 - Left
ventricular systolic dysfunction”). Conversely, ICD-10 terms are
substantially less specific (ICD terms “I50.0 Congestive heart fail-
ure” and “I50.9 Heart failure, unspecified”) and do not allow for
this distinction. As a rule, for overlapping diagnoses across multiple
sources, CALIBER phenotypes utilize the source with the highest
clinical resolution to ascertain disease status.
Figure 4. Risk factors for initial presentation of heart failure (HF) phenotype: hazard ratio (HR) and 95% confidence interval of smoking status, type 2 diabetes mel-
litus (T2DM), systolic blood pressure (BP) and heart rate based on previously published CALIBER studies29,75,76 compared with estimates obtained from investiga-
tor-led studies derived using manually curated research data.77–80 All individual analyses have been adjusted for age and sex and other covariates. Scale: 279 
215 mm (72  72 dots per inch).
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We found that diagnosis terms in primary care using Read terms
were not always informative and could not directly be used to ascer-
tain particular phenotypes. For example, when attempting to create
a dietary phenotype, we identified 173 Read terms related to nutri-
tion, which were recorded across 5.6 million diagnosis events. Only
8% of these, however, were sufficiently informative to infer a partic-
ular nutritional diet (for example, low-fat diet, gluten-free diet, dia-
betic diet, or low-sodium diet). The majority of terms used were
generic terms that carried little information (“8CA4.00 Patient ad-
vised re diet” or “9N0H.00 Seen in dietician clinic”) and could not
be used for ascertaining a phenotype with reasonable performance.
While such terms could potentially be utilized as supporting infor-
mation for other phenotypes (for example, diabetic diet as evidence
of diabetes) they cannot be used to ascertain a phenotype directly.
We observed that clinically informed combinations of informa-
tion across EHR sources improves case detection. All disease and
syndrome phenotypes (n¼35) utilized information sourced from
primary care and hospital care EHR and roughly half (n¼18) uti-
lized cause-specific mortality information recorded in the national
death register. In general, we considered EHR sources complemen-
tary to each other with each providing a different aspect of a
patient’s disease state (chronic vs acute) rather than denote one as
the authoritative source of information. One notable exception to
this is mortality, in which we used the ONS date of death as the
“gold standard,” as studies have shown that discrepancies exist be-
tween the recorded death dates in primary care EHR and the date
recorded on the death certificate (ONS). A previous study67 of
118 571 deaths in England showed that a discrepancy existed in al-
most a quarter of deaths. Considerable variation was observed be-
tween GP practices on the degree of such discrepancies (in the
majority of cases, the date of death recorded by the GP was after the
date of death recorded on the death certificate). This is because GPs
do not routinely see the death certificate (which is the definitive re-
cord of time and cause of death) and there is no legal obligation for
them to record the date of death accurately. If there is a delay in
their receipt of notification of death, they might record the date of
death as the date of notification, or the date the patient’s record was
closed, rather than the actual date of death. In line with previous lit-
erature we therefore used the ONS as the “gold standard” for ascer-
taining mortality.
A major effort of CALIBER has been to create longitudinal dis-
ease phenotypes that capture early and late manifestations of dis-
ease. We observed that the proportion of cases contributed by each
EHR source differed by age at diagnosis: patients identified in sec-
ondary care EHR were substantially older than were those identified
in primary care. For example, substantially more atrial fibrillation
cases were identified in secondary care EHR rather than in primary
care (32 930 cases compared with 11 068 from primary care), and
using only a single source would have introduced bias and underesti-
mated the incidence of disease. Conversely, type 2 diabetes cases
were exclusively identified through primary care EHR with no cases
identified exclusively in hospital EHR due to the fact that, such as
other diseases such as hypertension, diagnosis, and management, is
almost entirely performed in primary care.
Validation (Table 2) was a critical step for assessing the accuracy
of EHR-derived phenotypes. We did not consider algorithm valida-
tion as a finite task, but rather as a constantly evolving process due
to the underlying complexity of EHR data and the processes which
generate them.68 We sought to address the spectrum of validation
views and developed an approach that captures 6 levels of evidence.
The majority of disease and syndrome phenotypes examined inci-
dence estimates across different EHR sources and consistency with
previous associations in terms of disease etiology and prognosis.
Validation was more restricted in biomarker and lifestyle risk factor
phenotypes because information was derived from only 1 particular
source (in the case of biomarkers, measurements were exclusively
identified in primary care). Clinician case note review was consid-
ered the “gold standard” of phenotype validation that enables PPV
or NPV calculations but access to medical records was not widely
available, and thus we could only perform this in a single instance.
Prognostic validation was one of the main validation approaches
where consistency with previously reported findings provided a
degree of confidence in terms of phenotype validity (for exposures,
outcomes, and covariates used in the analyses). Inconsistent results,
however, were possible and could be explained due to multiple fac-
tors such as different health settings and sources of data, healthcare
process factors and workflows and uncomparable definitions.
In terms of the complete hospital interaction, HES data are a
snapshot of the patient journey as data are collected for hospital re-
imbursement.8,52 Hospital records are converted into diagnosis and
procedure codes locally (following an existing protocol) at each hos-
pital and submitted to the NHS. HES data are provided to research-
ers with identifiers for hospitals removed to protect patient
anonymity as a common identifier is used across HES and CPRD GP
practices, which have a substantially smaller catchment area. As
such, we were unable to assess the effect of site-level variability in
terms of data capture and quality and phenotype validity. Multiple
initiatives, however, exist for obtaining raw hospital records for
research, such as the National Institute for Health Research Health
Informatics Collaborative, which links 11 intensive care units in 5
hospitals for research (>18 000 patients, >21 000 admissions, me-
dian 1030 time-varying measures).69 Crucially, these initiatives will
enable researchers to have access to raw hospital data, including free
text, for creating and validating phenotypes and will create a feed-
back loop with clinical care that will provide detailed information
on the healthcare processes generating the data (critical for pheno-
typing) and drive data standardization and quality.
CALIBER phenotyping algorithms are rule-based, deterministic,
and provide a framework on which future phenotypes can be cre-
ated. While our approach yields robust and accurate algorithms, it
does not scale with our ambition to create and curate thousands of
high-quality phenotypes (and their validation) that capture the en-
tire human phenome. To do this, research is required on high-
throughput phenotyping involving supervised and unsupervised
learning approaches and natural language processing.70 Such meth-
ods can generate thousands of phenotypes and discover hidden asso-
ciations within clinical data in a fraction of the current cost and
time requirements and with minimal human intervention. Robust
approaches for classifying phenotype complexity are required to en-
sure proportional resourcing for phenotyping.71 Finally, a key next
step is to use the 6 sites of the recently funded Health Data Research
UK national institute to scale up the number of phenotypes created
and curated using UK EHR.
The use of a common data model to map between the clinical
terminologies used across EHR sources, such as the Observational
Medical Outcomes Partnership Common Data Model can poten-
tially address some of the labor-intensive tasks associated with phe-
notyping. For example, the translation from phenotype definition to
SQL for data extraction was manual due to the lack of an estab-
lished storage format72 for the algorithms and variable schema
across EHR sources. Observational Medical Outcomes Partnership
Common Data Model can potentially act as Relational Database
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Table 2. Systematic validation of the CALIBER EHR-derived phenotypes for HF, AMI, and bleeding across 6 approaches of evidence: cross-
EHR concordance, case-note review, etiology, prognosis, genetic associations, and external populations
Validation domain Description What has been done
HF AMI Bleeding
Cross-EHR source
concordance
To what extent is the
phenotype concor-
dant across EHR
sources?
The proportion of HF
cases recorded in pri-
mary care and hospital
care EHR was 27%31
The proportion of nonfatal
AMI defined across pri-
mary care, hospital care,
and disease registry was
32%29
The proportion of bleeding
events recorded in primary
care and hospital care was
12%, with 47% of bleed-
ing events recorded only in
primary care and 12%
only in hospital care
Case-note review What is the PPV and
the NPV when
comparing the al-
gorithm with clini-
cian review of case
notes or “gold
standard” source of
information?
Compared with AMI defined
in the disease registry, the
PPV of AMI recorded in
primary care was 92.2%
(95% CI, 91.6%-92.8%)
and in hospital admissions
was 91.5% (95% CI,
90.8%-92.1%)29
Compared through indepen-
dent review by 2 clinicians,
the PPV of bleeding events
identified through the phe-
notyping algorithm was
0.88
Etiology Are the prospective
associations with
risk actors consis-
tent with previous
evidence?
Type 2 diabetes,84 sys-
tolic/diastolic blood
pressure,32 heart
rate,85 socioeconomic
deprivation,86 alcohol
consumption,87 smok-
ing,88 ethnicity,44
AMI,29 depression,89
neutrophil counts,90
eosinophil/lymphocyte
counts,91 atrial fibrilla-
tion,30 sex92
Type 2 diabetes,84 systolic/di-
astolic blood pressure,32
heart rate,85 socioeco-
nomic deprivation,86 alco-
hol consumption,87
smoking,88 ethnicity,44
AMI,29 depression,89 neu-
trophil counts,90 eosino-
phil/lymphocyte counts,91
atrial fibrillation,30 influ-
enza infection,93 ischemic
presentations,94 sex92
At 5 y, 29.1% (95% CI,
28.2%-29.9%) of atrial fi-
brillation patients, 21.9%
(95% CI, 21.2%-22.5%)
of myocardial infarction
patients, 25.3% (95% CI,
24.2%-26.3%) of unstable
angina patients and 23.4%
(95% CI, 23.0%-23.8%)
of stable angina had bleed-
ing of any kind
Prognosis Are the risks of subse-
quent events plausi-
ble?
Corrected for age and
sex, HF was strongly
associated with mortal-
ity, with HRs for all-
cause mortality ranging
from 7.01 (95% CI,
6.83-7.20) to 7.23
(95% CI, 7.03-7.43),
and up to 15.38 (95%
CI, 15.02-15.83) for
patients in primary
care with acute HF
hospitalization, pri-
mary care only, and
patients hospitalized
but no primary care re-
cord31
Patients with myocardial in-
farction identified in the
disease registry had lower
crude 30-d mortality
(10.8%; 95% CI, 10.2%-
11.4%) than did those
identified in hospital care
(13.9%; 95% CI, 13.3%-
14.4%) or in primary care
(14.9%; 95% CI, 14.4%-
15.5%) (Figure 3+). At 1
year, however, mortality
was similar in all 3 groups,
at around 20%29
Of the 24 479 patients with
AMI, 5775 (23.6%) devel-
oped HF during a median
follow-up of 3.7 years (inci-
dence rate per 1000 person-
years, 63.8; 95% CI, 62.2-
65.5)95
The HR for all-cause mortal-
ity was 1.98 (95% CI,
1.86-2.11) for primary
care bleeding with markers
of severity, and 1.99 (95%
CI, 1.92-2.05) for hospital-
ized bleeding without
markers of severity, com-
pared with patients with
no bleeding
Genetic
associations
Are the observed ge-
netic associations
plausible and con-
cordance with pre-
vious evidence?
Consistent direction and
magnitude of associations
were replicated in 67
(97%) of previously
reported genetic variants4
(continued)
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Management System agnostic schema which standardized analytical
tools can be deployed on and has been shown to be robust73,74 and
we are currently in the process of evaluating the fidelity of the data
transformation. We have additionally evaluated different
approaches (Semantic Web Technologies, openEHR)75,76 for storing
phenotype definitions in a computable format that can enable high-
throughput phenotyping and eliminate the need for manual human-
driven translation to SQL queries. Given that all of UK primary care
EHR data are hosted on 4 clinical information systems vendors,
there is a real opportunity to create computable phenotypes which
can be utilized across the NHS.77 To accomplish this, information
exchange standards (for example, Fast Healthcare Interoperability
Resources78) have to be utilized and combined with approaches
such as the Phenotype Execution and Modeling Architecture79 and
the Measure Authoring Tool.80
CONCLUSION
We have demonstrated the strengths and challenges of phenotyping
national UK EHR data using 3 exemplars (HF, AMI, bleeding) and
have exemplified the United Kingdom’s national EHR phenomics
platform. In this manuscript, we presented the CALIBER platform
as a framework for using national EHR from primary and secondary
health care, disease and national mortality registries. CALIBER is
analogous and complementary to other leading initiatives, (for ex-
ample, eMERGE), in that it ensures best practice and reproducibility
for creating and validating EHR-derived phenotypes.81,82 In con-
trast with eMERGE, however, which uses secondary care data
(higher proportion of disease), CALIBER exploits primary care
EHRs, which contain healthy and ill individuals. Importantly, the
approaches described here are potentially scalable or adaptable to
the entire UK population of 65 million.
Through CALIBER we provide a framework for the consistent
definition, use, and reuse of EHR-derived phenotypes from national
UK EHR sources for observational research: (1) high-resolution clin-
ical epidemiology using national EHRs examining disease etiology
or prognosis96 or (2) genetic epidemiology studies through the UK
Biobank and Genomics England investigating simple and complex
traits across populations. One of the primary audiences of CALIBER
phenotypes is international: U.S. investigators account for a third
of studies using UK primary care EHRs18 and two-thirds of UK
Biobank studies are carried out by U.S. investigators. Additionally,
the controlled clinical terminologies used in UK EHRs are directly
translatable and transferable to the United States, for example,
Read terms (CTV3 [Clinical Terms Version 3]) are part of
SNOMED-CT, and ICD-9 Clinical Modification to ICD-10 map-
pings exist. As Phenotype Knowledgebase and other
initiatives evolve, establishing links across national portals83 and in-
frastructure can enable cross-biobank analyses of complex or rare
phenotypes.7
The creation of a national phenomics platform through CALI-
BER provides an opportunity for the UK EHR community to inter-
act, nationally and internationally, and connects data producers and
consumers. Researchers can deposit phenotyping algorithms in the
Portal for others to download, refine, and use. EHR users (such as
clinicians) can view these algorithms and understand how the data
they record are being used for research.
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Table 2.. continued
Validation domain Description What has been done
HF AMI Bleeding
External
populations
Has the algorithm
been tested (in any
of the previous vali-
dation domains) in
different countries?
We observed high 3-y crude
cumulative risks of all-
cause death (from 19.6%
[England] to 30.2%
[United States]); the com-
posite of AMI, stroke, or
death (from 26.0%
[France] to 36.2% [United
States]); and hospitalized
bleeding (from 3.1%
[France] to 5.3% [United
States])64
AMI: acute myocardial infarction; CI: confidence interval; EHR: electronic health record; HF: heart failure; HR: hazard ratio; NPV: negative predictive value;
PPV: positive predictive value.
12 Journal of the American Medical Informatics Association, 2019, Vol. 0, No. 0
D
ow
nloaded from
 https://academ
ic.oup.com
/jam
ia/advance-article-abstract/doi/10.1093/jam
ia/ocz105/5536916 by U
niversity C
ollege London Library user on 23 July 2019
and Wellcome Trust (MR/K006584/1). This article represents inde-
pendent research part funded (AG-I, KD, NKF) by the National Insti-
tute for Health Research Biomedical Research Centre at University
College London Hospitals. HH is an National Institute for Health
Research Senior Investigator. ADS is a THIS Institute postdoctoral
fellow. VK is supported by the Wellcome Trust (WT 110284/Z/15/
Z). SD is supported by an Alan Turing Fellowship. RSP is funded by
a BHF Fellowship FS/14/76/30933. ADH is an NIHR Senior Investi-
gator. RTL is supported by a UKRI Rutherford Fellowship.
AUTHOR CONTRIBUTIONS
Conceived and designed the study: SD, HH. Analyzed the data: SD,
LP, LJH, ADS, GF. Contributed reagents/materials/analysis tools:
AGI, KD, NFK, GF, ADS, RD, VK. Wrote the paper: SD, HH. Com-
mented on manuscript, contributed to revisions: AGI, KD, NFK,
GF, AB, LP, RD, LJH, VK, RTL, LP, RSP, ADS, ADH, CS, HH. All
authors reviewed and interpreted the results, read and approved the
final version.
ACKNOWLEDGMENTS
This study was approved by the Medicines and Healthcare Products Regula-
tory Agency Independent Scientific Advisory Committee protocol references:
11_088, 12_153R, 16_221, 18_029R2, 18_159R. This study is based in part
on data from the Clinical Practice Research Datalink obtained under license
from the UK Medicines and Healthcare products Regulatory Agency. The
data are provided by patients and collected by the NHS as part of their care
and support. The interpretation and conclusions contained in this study are
those of the author(s) alone. Hospital Episode Statistics Copyright (2019) is
reused with the permission of The Health & Social Care Information Centre.
All rights reserved. The Office of Population Censuses and Surveys Classifica-
tion of Interventions and Procedures, codes, terms and text is Crown copy-
right (2016) published by Health and Social Care Information Centre, also
known as NHS Digital and licensed under the Open Government Licence
(available at www.nationalarchives.gov.uk/doc/open-government-licence/
open-government-licence.htm). This study was carried out as part of the CAL-
IBER programme (https://www.ucl.ac.uk/health-informatics/caliber). CALI-
BER, led from the UCL Institute of Health Informatics, is a research resource
consisting of linked electronic health records phenotypes, methods and tools,
specialized infrastructure, and training and support. The views expressed are
those of the author(s) and not necessarily those of the National Health Ser-
vice, the National Institute for Health Research, or the Department of Health.
This paper represents independent research [part] funded by the National In-
stitute for Health Research (NIHR) Biomedical Research Centre at South
London and Maudsley NHS Foundation Trust and King’s College London.
The views expressed are those of the author(s) and not necessarily those of the
NHS, the NIHR or the Department of Health and Social Care.
Conflict of interest statement. None declared.
REFERENCES
1. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and
use of the general practice research database as an example of a UK pri-
mary care data resource. Ther Adv Drug Saf 2012; 3 (2): 89–99.
2. Ludwick DA, Doucette J. Adopting electronic medical records in primary
care: lessons learned from health information systems implementation ex-
perience in seven countries. Int J Med Inform 2009; 78 (1): 22–31.
3. Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB. The
100 000 genomes project: bringing whole genome sequencing to the NHS.
BMJ 2018; 361: k1687.
4. Denaxas SC, Fatemifar G, Patel R, Hemingway H. Deriving research-
quality phenotypes from national electronic health records to advance pre-
cision medicine: a UK Biobank case-study. In: Proceedings of the BHI-
2017 International Conference on Biomedical and Health Informatics.
Orlando, FL: IEEE Engineering in Medicine and Biology Society (EMBS);
2017.
5. Schnier C, Denaxas S, Eggo R, et al. Identification and validation of myo-
cardial infarction and stroke outcomes at scale in UK Biobank. Int J Pop
Data Sci 2017; 1 (1): 337. doi: 10.23889/ijpds.v1i1.358.
6. Wei W-Q, Denny JC. Extracting research-quality phenotypes from elec-
tronic health records to support precision medicine. Genome Med 2015;
7: 41.
7. Casey JA, Schwartz BS, Stewart WF, Adler NE. Using electronic health
records for population health research: a review of methods and applica-
tions. Annu Rev Public Health 2016; 37 (1): 61–81.
8. Denaxas SC, Asselbergs FW, Moore JH. The tip of the iceberg: challenges
of accessing hospital electronic health record data for biological data min-
ing. BioData Min 2016; 9: 29.
9. Hemingway H, Asselbergs FW, Danesh, J, et al. Big data from electronic
health records for early and late translational cardiovascular research:
challenges and potential. Eur Heart J 2018; 39 (16): 1481–95.
10. Gottesman O, Kuivaniemi H, Tromp G, et al. The electronic medical
records and genomics (eMERGE) network: past, present, and future.
Genet Med 2013; 15 (10): 761–71.
11. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale
de-identified DNA biobank to enable personalized medicine. Clin Phar-
macol Ther 2008; 84 (3): 362–9.
12. Gaziano JM, Concato J, Brophy M, et al. Million veteran program: a
mega-biobank to study genetic influences on health and disease. J Clin
Epidemiol 2016; 70: 214–23.
13. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J
Med 2015; 372 (9): 793–5.
14. Doiron D, Raina P, Fortier I. Linkage between cohorts and health care uti-
lization data: meeting of Canadian stakeholders workshop participants.
Linking Canadian population health data: maximizing the potential of co-
hort and administrative data. Can J Public Health 2013; 104 (3):
e258–61.
15. Holman CDJ, Bass AJ, Rosman DL, et al. A decade of data linkage in
Western Australia: strategic design, applications and benefits of the WA
data linkage system. Aust Health Rev 2008; 32 (4): 766–77.
16. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish web-system
for enhancement and development of evidence-based care in heart disease
evaluated according to recommended therapies (SWEDEHEART). Heart
2010; 96 (20): 1617–21.
17. Jensen AB, Moseley PL, Oprea TI, et al. Temporal disease trajectories con-
densed from population-wide registry data covering 6.2 million patients.
Nat Commun 2014; 5: 4022.
18. Vezyridis P, Timmons S. Evolution of primary care databases in UK: a sci-
entometric analysis of research output. BMJOpen 2016; 6 (10): e012785.
19. Springate DA, Kontopantelis E, Ashcroft DM, et al. ClinicalCodes: an
online clinical codes repository to improve the validity and reproducibil-
ity of research using electronic medical records. PLoS One 2014; 9 (6):
e99825.
20. Al Sallakh MA, Vasileiou E, Rodgers SE, Lyons RA, Sheikh A, Davies GA.
Defining asthma and assessing asthma outcomes using electronic
health record data: a systematic scoping review. Eur Respir J 2017; 49:
1700204.
21. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple
health and social care datasets. BMCMed Inform Decis Mak 2009; 9: 3.
22. Ford DV, Jones KH, Verplancke J-P, et al. The SAIL databank: building a
national architecture for e-health research and evaluation. BMC Health
Serv Res 2009; 9: 157.
23. Jammeh EA, Carroll CB, Pearson SW, et al. Machine-learning based iden-
tification of undiagnosed dementia in primary care: a feasibility study.
BJGPOpen 2018; 2 (2): bjgpopen18X101589.
24. Zhou S-M, Fernandez-Gutierrez F, Kennedy J, et al. Defining disease phe-
notypes in primary care electronic health records by a machine learning
approach: a case study in identifying rheumatoid arthritis. PLoS One
2016; 11 (5): e0154515.
Journal of the American Medical Informatics Association, 2019, Vol. 0, No. 0 13
D
ow
nloaded from
 https://academ
ic.oup.com
/jam
ia/advance-article-abstract/doi/10.1093/jam
ia/ocz105/5536916 by U
niversity C
ollege London Library user on 23 July 2019
25. Williams R, Kontopantelis E, Buchan I, Peek N. Clinical code set engineering
for reusing EHR data for research: a review. J Biomed Inform 2017; 70: 1–13.
26. Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical
record-based phenotyping algorithms: results and lessons learned from the
eMERGE network. J AmMed Inform Assoc 2013; 20 (e1): e147–54.
27. Banda JM, Seneviratne M, Hernandez-Boussard T, Shah NH. Advances in
Electronic Phenotyping: From Rule-Based Definitions to Machine Learn-
ing Models. Annu Rev Biomed Data Sci 2018; 1:1, 53–68.
28. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA,
Richards MA. Cancer recording and mortality in the general practice re-
search database and linked cancer registries. Pharmacoepidemiol Drug
Saf 2013; 22 (2): 168–75.
29. Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity
of recording acute myocardial infarction events in primary care, hospital
care, disease registry, and national mortality records: cohort study. BMJ
2013; 346: f2350.
30. Morley KI, Wallace J, Denaxas SC, et al. Defining disease phenotypes us-
ing national linked electronic health records: a case study of atrial fibrilla-
tion. PLoS One 2014; 9 (11): e110900.
31. Koudstaal S, Pujades-Rodriguez M, Denaxas S, et al. Prognostic burden of
heart failure recorded in primary care, acute hospital admissions, or both:
a population-based linked electronic health record cohort study in 2.1 mil-
lion people. Eur J Heart Fail 2017; 19 (9): 1119–27.
32. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence
of twelve cardiovascular diseases: lifetime risks, healthy life-years lost,
and age-specific associations in 125 million people. Lancet 2014; 383
(9932): 1899–911.
33. Wu H, Toti G, Morley KI, et al. SemEHR: A general-purpose semantic
search system to surface semantic data from clinical notes for tailored
care, trial recruitment, and clinical research. J Am Med Inform Assoc
2018; 25 (5): 530–7.
34. Ford E, Carroll JA, Smith HE, Scott D, Cassell JA. Extracting information
from the text of electronic medical records to improve case detection: a
systematic review. J AmMed Inform Assoc 2016; 23 (5): 1007–15.
35. Rubbo B, Fitzpatrick NK, Denaxas S, et al. Use of electronic health
records to ascertain, validate and phenotype acute myocardial infarction:
A systematic review and recommendations. Int J Cardiol 2015; 187:
705–11.
36. World Health Organization. Others. ICD-10: The ICD-10 Classification
of Mental and Behavioural Disorders: Diagnostic Criteria for Research.
Geneva, Switzerland: World Health Organization; 1993.
37. Jarvis B, Johnson T, Butler P, et al. Assessing the impact of electronic
health records as an enabler of hospital quality and patient satisfaction.
Acad Med 2013; 88 (10): 1471–7.
38. Goodman SN, Fanelli D, Ioannidis J. What does research reproducibility
mean? Sci Transl Med 2016; 8 (341): 341ps12.
39. Denaxas SC, George J, Herrett E, et al. Data resource profile: cardiovascu-
lar disease research using linked bespoke studies and electronic health
records (CALIBER). Int J Epidemiol 2012; 41 (6): 1625–38.
40. Gallagher AM, Puri S, van Staa TP. 528. Linkage of the general practice
research database (gprd) with other data sources. Pharmacoepidemiol
Drug Saf 2011; 20: 230–1.
41. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clini-
cal practice research datalink (CPRD). Int J Epidemiol 2015; 44 (3):
827–36.
42. O’Neil M, Payne C, Read J. Read codes version 3: a user led terminology.
Methods Inf Med 1995; 34 (1–2): 187–92.
43. Datta-Nemdharry P, Thomson A, Beynon J. Opportunities and challenges
in developing a cohort of patients with type 2 diabetes mellitus using elec-
tronic primary care data. PLoS One 2016; 11 (11): e0162236.
44. George J, Mathur R, Shah AD, et al. Ethnicity and the first diagnosis of a
wide range of cardiovascular diseases: associations in a linked electronic
health record cohort of 1 million patients. PLoS One 2017; 12 (6):
e0178945.
45. Bhaskaran K, Forbes HJ, Douglas I, Leon DA, Smeeth L. Representative-
ness and optimal use of body mass index (BMI) in the UK clinical practice
research datalink (CPRD). BMJ Open 2013; 3 (9): e003389.
46. Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability
of ethnicity data in UK-based primary care and hospital databases. J Pub-
lic Health (Oxf) 2014; 36 (4): 684–92.
47. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and
validity of diagnoses in the general practice research database: a system-
atic review. Br J Clin Pharmacol 2010; 69 (1): 4–14.
48. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data Re-
source Profile: Hospital Episode Statistics Admitted Patient Care (HES
APC). Int J Epidemiol 2017; 46 (4): 1093–1093i.
49. American Medical Association. Current Procedural Terminology: CPT.
Chicago, IL, USA: American Medical Association; 2007.
50. Herrett E, Smeeth L, Walker L, Weston C; MINAP Academic Group. The
myocardial ischaemia national audit project (MINAP). Heart 2010; 96:
1264–7.
51. Jordan H, Roderick P, Martin D. The index of multiple deprivation 2000
and accessibility effects on health. J Epidemiol Community Health 2004;
58 (3): 250–7.
52. Farrar S, Yi D, Sutton M, Chalkley M, Sussex J, Scott A. Has payment by
results affected the way that English hospitals provide care? Difference-in-
differences analysis. BMJ 2009; 339: b3047.
53. Burns EM, Rigby E, Mamidanna R, et al. Systematic review of discharge
coding accuracy. J Public Health (Oxf) 2012; 34 (1): 138–48.
54. NHS Data Quality Maturity Index. NHS Digital. https://digital.nhs.uk/
data-and-information/data-tools-and-services/data-services/data-quality.
Accessed March 13, 2019.
55. Aronson AR. Effective mapping of biomedical text to the UMLS metathe-
saurus: the MetaMap program. Proc AMIA Symp 2001; 2001: 17–21.
56. Bodenreider O. The unified medical language system (UMLS): integrating
biomedical terminology. Nucleic Acids Res 2004; 32: D267–70.
57. Jackson R, Kartoglu I, Stringer C, et al. CogStack-experiences of deploy-
ing integrated information retrieval and extraction services in a large Na-
tional Health Service Foundation Trust hospital. BMC Med Inform Decis
Mak 2018; 18: 47.
58. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of
phenome-wide association study of electronic medical record data and
genome-wide association study data. Nat Biotechnol 2013; 31 (12):
1102–10.
59. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum
Genet 2007; 81 (3): 559–75.
60. Nikpay M, Goel A, Won H-H, et al. A comprehensive 1, 000 Genomes-
based genome-wide association meta-analysis of coronary artery disease.
Nat Genet 2015; 47 (10): 1121–30.
61. Kraker P, Lex E, Gorraiz J, Gumpenberger C, Peters I. Research data ex-
plored II: the anatomy and reception of Figshare. arXiv 2015 Jun 26 [E-
pub ahead of print].
62. UCL. CALIBER publications. UCL Institute of Health Informatics.
https://www.ucl.ac.uk/health-informatics/caliber/publications. Accessed
April 26, 2018.
63. Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-
specific risks, severity, time course, and outcome of bleeding on long-term
antiplatelet treatment after vascular events: a population-based cohort
study. Lancet 2017; 390 (10093): 490–9.
64. Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health
records from four countries to evaluate chronic disease outcomes: a study
in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin
Outcomes 2016; 2 (3): 172–83.
65. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction
equations in 400 000 primary care patients in New Zealand: a derivation
and validation study. Lancet 2018; 391 (10133): 1897–907.
66. Shah AD, Thornley S, Chung S-C, Denaxas S, Jackson R, Hemingway H.
White cell count in the normal range and short-term and long-term mor-
tality: international comparisons of electronic health record cohorts in En-
gland and New Zealand. BMJ Open 2017; 7 (2): e013100.
67. Harshfield A, Abel GA, Barclay S, et al Do GPs accurately record date of
death? A UK observational analysis. BMJ Support Palliat Care 2018 Jun
27 [E-pub ahead of print]. doi: 10.1136/bmjspcare-2018-001514.
14 Journal of the American Medical Informatics Association, 2019, Vol. 0, No. 0
D
ow
nloaded from
 https://academ
ic.oup.com
/jam
ia/advance-article-abstract/doi/10.1093/jam
ia/ocz105/5536916 by U
niversity C
ollege London Library user on 23 July 2019
68. Denaxas SC, Morley KI. Big biomedical data and cardiovascular disease
research: opportunities and challenges. Eur Heart J Qual Care Clin Out-
comes 2015; 1 (1): 9–16.
69. Harris S, Shi S, Brealey D, et al. Critical care health informatics
collaborative (CCHIC): data, tools and methods for reproducible re-
search: a multi-centre UK intensive care database. Int J Med Inform 2018;
112: 82–9.
70. Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health
records. J AmMed Inform Assoc 2013; 20 (1): 117–21.
71. Hripcsak G, Albers DJ. High-fidelity phenotyping: richness and freedom
from bias. J AmMed Inform Assoc 2017; 25(3): 289–294.
72. Xu, J, Rasmussen, LV Shaw, PL, et al. Review and evaluation of
electronic health records-driven phenotype algorithm authoring tools for
clinical and translational research. J Am Med Inform Assoc 2015; 22:
1251–60.
73. Schuemie MJ, Gini R, Coloma PM, et al. Replication of the OMOP exper-
iment in Europe: evaluating methods for risk identification in electronic
health record databases. Drug Saf 2013; 36 suppl 1: S159–69.
74. Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical prac-
tice research datalink conversion to the OMOP common data model.
Drug Saf 2014; 37 (11): 945–59.
75. Papez V, Denaxas S, Hemingway H. Evaluating OpenEHR for storing
computable representations of electronic health record phenotyping algo-
rithms. In: 2017 IEEE 30th International Symposium on Computer-Based
Medical Systems (CBMS). IEEE Computer Society; 2017: 509–14.
76. Papez V, Denaxas S, Hemingway H. Evaluation of semantic web technol-
ogies for storing computable definitions of electronic health records phe-
notyping algorithms. AMIA Annu Symp Proc 2017; 2017: 1352–61.
77. Mo H, Thompson WK, Rasmussen LV. Desiderata for computable repre-
sentations of electronic health records-driven phenotype algorithms. J Am
Med Inform Assoc 2015; 22 (6): 1220–30.
78. Bender D, Sartipi K. HL7 FHIR: an agile and RESTful approach
to healthcare information exchange. In: Proceedings of the 26th IEEE In-
ternational Symposium on Computer-Based Medical Systems; 2013:
326–31.
79. Jiang G, Kiefer RC, Rasmussen LV, et al. Developing a data element re-
pository to support EHR-driven phenotype algorithm authoring and exe-
cution. J Biomed Inform 2016; 62: 232–42.
80. Thompson WK, Rasmussen LV, Pacheco JA, et al. An evaluation of the
NQF quality data model for representing electronic health record
driven phenotyping algorithms. AMIA Annu Symp Proc 2012; 2012:
911–20.
81. Denaxas S, Direk K, Gonzalez-Izquierdo A, et al. Methods for enhancing
the reproducibility of biomedical research findings using electronic health
records. BioData Min 2017; 10: 31.
82. Denaxas S, Gonzalez-Izquierdo A, Pikoula M, et al. Methods for enhanc-
ing the reproducibility of observational research using electronic health
records: preliminary findings from the CALIBER resource. In: 2017 IEEE
30th International Symposium on Computer-Based Medical Systems
(CBMS); 2017: 506–8.
83. Kirby JC, Speltz P, Rasmussen LV, et al. PheKB: a catalog and workflow
for creating electronic phenotype algorithms for transportability. J Am
Med Inform Assoc 2016; 23 (6): 1046–52.
84. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and inci-
dence of cardiovascular diseases: a cohort study in 19 million people.
Lancet Diabetes Endocrinol 2015; 3: 105–13.
85. Archangelidi O, Pujades-Rodriguez M, Timmis A, Jouven X, Denaxas S,
Hemingway H. Clinically recorded heart rate and incidence of 12 coro-
nary, cardiac, cerebrovascular and peripheral arterial diseases in 233, 970
men and women: A linked electronic health record study. Eur J Prev Car-
diol 2018; 25 (14): 1485–95.
86. Pujades-Rodriguez M, Timmis A, Stogiannis D, et al. Socioeconomic dep-
rivation and the incidence of 12 cardiovascular diseases in 1.9 million
women and men: implications for risk prediction and prevention. PLoS
One 2014; 9 (8): e104671.
87. Bell S, Daskalopoulou M, Rapsomaniki E, et al. Association between clini-
cally recorded alcohol consumption and initial presentation of 12 cardio-
vascular diseases: population based cohort study using linked health
records. BMJ 2017; 356: j909.
88. Pujades-Rodriguez M, George J, Shah AD, et al. Heterogeneous associa-
tions between smoking and a wide range of initial presentations of cardio-
vascular disease in 1937360 people in England: lifetime risks and
implications for risk prediction. Int J Epidemiol 2015; 44 (1): 129–41.
89. Daskalopoulou M, George J, Walters K, et al. Depression as a risk factor
for the initial presentation of twelve cardiac, cerebrovascular, and periph-
eral arterial diseases: data linkage study of 1.9 million women and men.
PLoS One 2016; 11 (4): e0153838.
90. Shah AD, Denaxas S, Nicholas O, Hingorani AD, Hemingway H. Neutro-
phil counts and initial presentation of 12 cardiovascular diseases: a CALI-
BER cohort study. J Am Coll Cardiol 2017; 69 (9): 1160–9.
91. Shah AD, Denaxas S, Nicholas O, Hingorani AD, Hemingway H. Low eo-
sinophil and low lymphocyte counts and the incidence of 12 cardiovascu-
lar diseases: a CALIBER cohort study. Open Heart 2016; 3 (2): e000477.
92. George J, Rapsomaniki E, Pujades-Rodriguez M, et al. How does cardio-
vascular disease first present in women and men? Incidence of 12 cardio-
vascular diseases in a contemporary cohort of 1, 937, 360 people.
Circulation 2015; 132 (14): 1320–8.
93. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection
and risk of acute myocardial infarction in England and Wales: a CALIBER
self-controlled case series study. J Infect Dis 2012; 206 (11): 1652–9.
94. Herrett E, Bhaskaran K, Timmis A, Denaxas S, Hemingway H, Smeeth L.
Association between clinical presentations before myocardial infarction
and coronary mortality: a prospective population-based study using
linked electronic records. Eur Heart J 2014; 35 (35): 2363–71.
95. Gho J, Schmidt AF, Pasea L, et al. An electronic health records cohort
study on heart failure following myocardial infarction in England: inci-
dence and predictors. BMJ Open 2018; 8 (3): e018331.
96. Kuan V, et al. A chronological map of 308 physical and mental health con-
ditions from 4 million individuals in the English National Health Service.
The Lancet Digital Health 2019; 1:e63–77.
Journal of the American Medical Informatics Association, 2019, Vol. 0, No. 0 15
D
ow
nloaded from
 https://academ
ic.oup.com
/jam
ia/advance-article-abstract/doi/10.1093/jam
ia/ocz105/5536916 by U
niversity C
ollege London Library user on 23 July 2019
